

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/501,179	02/10/2000	Zheng-Pin Wang	1887.0060002/RWE/KKV	3508
75	590 01/31/2002			
Sterne Kessler Goldstein & Fox PLLC			EXAMINER	
Attorneys at Law Suite 600 1100 New York Avenue NW Washington, DC 20005-3934			CANELLA, KAREN A	
			ART UNIT	PAPER NUMBER
			1642	13
			DATE MAILED: 01/31/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/501,179 Applica...t(s)

Wang et al

Karen Canella

Art Unit 1642



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 months MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

communication. - Failure to reply within the set or extended period for reply will, leading to the communication.	ication.	
Status 1) Responsive to communication(s) filed on		
2a) ☑ This action is FINAL. 2b) ☐ This action	ction is non-final.	
3) Since this application is in condition for allowance closed in accordance with the practice under Ex p	except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.	
Disposition of Claims		
4) X Claim(s) <u>1-26</u>	is/are pending in the application.	
4a) Of the above, claim(s)	is/are withdrawn from consideration.	
5) Claim(s)	is/are allowed.	
6) 💢 Claim(s) <u>1-26</u>	is/are rejected.	
	is/are objected to.	
	are subject to restriction and/or election requirement.	
Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on is/a 11) □ The proposed drawing correction filed on / 12) □ The oath or declaration is objected to by the Example 1.	$1/0/$ is: a) \square approved b) \square disapproved.	
Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign a) All b) Some* c) None of: 1. Certified copies of the priority documents had 2. Certified copies of the priority documents had 3. Copies of the certified copies of the priority application from the International But *See the attached detailed Office action for a list of 14) Acknowledgement is made of a claim for domest	documents have been received in this National Stage reau (PCT Rule 17.2(a)). the certified copies not received.	
Attachment(s)		
15) Notice of References Cited (PTO-892)	18] Interview Summary (PTO-413) Paper No(s).	
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Notice of Informal Patent Application (PTO-152)	
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	20] Other:	

Application/Control Number: 09/501,179 Page 2

Art Unit: 1642

DETAILED ACTION

Continued Prosecution Application

- 1. The request filed on November 1, 2001 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/501,179 is acceptable and a CPA has been established. An action on the CPA follows.
- 2. Claims 1-26 are pending and examined on the merits.

Claim Rejections - 35 USC § 112

- 3. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 4. The rejection of claims 6, 19 and 20 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, is maintained for reasons of record as applicant has not provided any amendments or arguments regarding the language the pending claims.
- 5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

 The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 6. The rejection of claims 1-26 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the

••

Application/Control Number: 09/501,179 Page 3

Art Unit: 1642

invention is maintained for reasons of record and in addition, from the evidence as set forth in Wang et al (Cancer, 2000, Vol. 88, pp. 2787-2795, reference AS of the IDS provided on November 11, 2001). Wang et al state on (page 2795, last paragraph):

"We are currently analyzing the profiles of these cell populations in view of the terminal pathway versus the living/multiplying pathway. Correlation of disease progression in these patients with the dynamic change of the circulating cancer cell population at different stages (in terms of total cell numbers and the distributions among classes/categories) may provide insight into the application of the circulating microtumor hypothesis described above to a clinical or diagnostic setting." As this paper represents the work of the instant inventor which was submitted for publication on April 23, 1999 and the instant specification has a priority date of February 10, 1999, it is further evidence that at the time the application was filed one of skill in the art would not be able to interpret the data obtained from the instant method of classifying cancer cells in terms of patient prognosis without undue experimentation. Further, this evidence corroborates the examiners rejection (page 3, lines 23-26) of the previous Office action which states that due to the lack of teachings in the specification regarding the link between the resulting classifications of isolated tumor cells in terms of absolute numbers and percentages and the positive diagnosis of metastatic cancer, one of skill in the art would not know how to use the instant claimed method.

Conclusion

7. Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p) on November 1, 2001 prompted the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 609(B)(2)(i). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 09/501,179 Page 4

Art Unit: 1642

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

ANTHONY C. CAPUTA
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Karen A. Canella, Ph.D.

Patent Examiner, Group 1642

January 13, 2002